Abstract
Over the past decades, numerous reports have covered the crucial role of multidrug resistance (MDR) transporters in the efficacy of various chemotherapeutic drugs. Specific cell membrane-associated transporters mediate drug resistance by effluxing a wide spectrum of toxic agents. Although several excellent reviews have addressed general aspects of drug resistance, this current review aims to highlight implications for the efficacy of folate-based and other types of chemotherapeutic drugs. Folates are vitamins that are daily required for many biosynthetic processes. Folate supplementation in our diet may convey protective effects against several diseases, including cancers, but folate supplementation also makes up an essential part of several current cancer chemotherapeutic regimens. Traditionally, the folate leucovorin, for instance, is used to reduce antifolate toxicity in leukemia or to enhance the effect of the fluoropyrimidine 5-fluorouracil in some solid tumors. More recently, it has also been noted that folic acid has the ability to increase antitumor activity of several structurally unrelated regimens, such as alimta/pemetrexed and cisplatin. Moreover, studies from our laboratory demonstrated that folates could modulate the expression and activity of at least two members of the MDR transporters: MRP1/ABCC1, and the breast cancer resistance protein BCRP/ABCG2. Thus, folate supplementation may have differential effects on chemotherapy: (1) reduction of toxicity, (2) increase of antitumor activity, and (3) induction of MRP1 and BCRP associated cellular drug resistance. In this review the role of MDR proteins is discussed in further detail for each of these three items from the perspective to optimally exploit folate supplementation for enhanced chemotherapeutic efficacy of both antifolate-based chemotherapy and other classes of chemotherapeutic drugs.
Similar content being viewed by others
Abbreviations
- BCRP:
-
Breast cancer resistance protein
- DHFR:
-
Dihydrofolate reductase
- FPGS:
-
Folylpolyglutamate synthetase
- GSH:
-
Glutathione
- MDR:
-
Multiple drug resistance
- MRPs:
-
Multidrug resistance proteins
- MTX:
-
Methotrexate
- TS:
-
Thymidylate synthase
- ABC:
-
ATP binding cassette transporters
References
Danø K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites. Biochim Biophys Acta 323:466–483
Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537–592
Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537–7552
Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22:7496–7511
Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21–53
Cole SP, Bhardwaj G, Gerlach J, Mackie JE, Grant C, Almquist KC, Stewart AJ, Kurz E, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
Dean M, Allikmets R (2001) Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33:475–479
Borst P, Evers R, Kool M, Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 146:347–357
Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302
Leslie EM, Deeley RG, Cole SP (2001) Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167:3–23
Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B (2003) The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140:133–143
Yabuuchi H, Shimizu H, Takayanagi S et al (2001) Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun 288:933–939
Broxterman HJ, Giaccone G, Lankelma J (1995) Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr Opin Oncol 7:532–540
Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833–4836
Leier I, Jedlitschky G, Buchholz U, Center M, Cole SP, Deeley RG, Keppler D (1996) ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J 314:433–437
Müller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, de Vries EG, Jansen PL (1994) Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033–13037
Ishikawa T, Akimaru K, Kuo MT, Priebe W, Suzuki M (1995) How does the MRP/GS-X pump export doxorubicin? J Natl Cancer Inst 87:1639–1640
König J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2 mediated drug resistance. Biochem Biophys Acta 1461:377–394
Hirohashi T, Suzuki H, Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 274:15181–15185
Schuetz JD, Connelly MC, Sun D et al (1999) MRP4: a previously unidentified factor in resistance to nucleotide-based antiviral drugs. Nat Med 5:1048–1051
Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc Natl Acad Sci USA 100:9244–9249
Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97:7476–7481
McAleer MA, Breen MA, White NL, Matthews N (1999) pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem 274:23541–23548
Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, Van der Born K, De Haas M, Van der Heiden I, Kaspers GJ, Wijnholds J, Jansen G, Peters GJ, Borst P (2005) The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 65:4425–4430
Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD (2002) Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62:6172–6177
Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64:4927–4930
Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD (2003) MRP8, ATP-binding cassette 11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J Biol Chem 278:29509–29514
Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD (2005) Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol 67:545–557
Flens MJ, Zaman GJ, van der Valk P, lzquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ (1996) Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237–1247
Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F, Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537–3547
Kool M, Van der Linden M, de Haas M, Baas F, Borst P (1999) Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 59:175–182
Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, van Helvoort A, de Jong MC, Hooijberg JH, Mol CA, van der Linden M, de Vree JM, van der Valk P, Elferink RP, Borst P, Scheper RJ (2000) Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60:5269–5277
Hipfner DR, Mao Q, Qiu W, Leslie EM, Gao M, Deeley RG, Cole SP (1999) Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. Localization of their epitopes to the nucleotide-binding domains of the protein. J Biol Chem 274:15420–15426
Nooter K, Westerman MA, Flens MJ, Zaman GJR, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, Graterna JW, Kok T, Eggermont AMM, Bosman FT, Stoter G (1995) Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1:1301–1310
Giaccone G, van Ark-Otte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans AM, Flens MJ, Scheper RJ, Pinedo HM (1996) MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer 66:760–767
Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G (1997) Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71:787–795
Kubo H, Sumizawa T, Koga K, Nishiyama K, Takebayashi Y, Chuman Y, Furukawa T, Akiyama S, Ohi Y (1996) Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas. Int J Cancer 69:488–494
Berger W, Elbling L, Hauptmann E, Micksche M (1997) Expression of the multidrug resistance associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73:84–93
Zervos PH, Allen RH, Thornton DE, Thiem PA (1997) Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Eur J Cancer (suppl)33, S18
Ohishi Y, Oda Y, Uchiumi T, Kobayashi H, Hirakawa T, Miyamoto S, Kinukawa N, Nakano H, Kuwano M, Tsuneyoshi M (2002) ATP binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8:3767–3775
Sauerbrey A, Voigt A, Wittig S, Hafer R, Zintl F (2002) Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma 43:875–879
Van den Heuvel-Eibrink MM, Sonneveld P, Pieters R (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38:94–110
Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186–193
Ikeda K, Oka M, Yamada Y, Soda H, Fukuda M, Kinoshita A, Tsukamoto K, Noguchi Y, Isomoto H, Takeshima F, Murase K, Kamihira S, Tomonaga M, Kohno S (1999) Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung resistance-protein (LRP) genes. Int J Cancer 82:599–604
Ogretmen B, Barredo JC, Safa AR (2000) Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 22:45–49
Ohno N, Tani A, Chen ZS, Uozumi K, Hanada S, Akiba S, Ren XQ, Furukawa T, Sumizawa T, Arima T, Akiyama SI (2001) Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res 7:3120–3126
Steinbach D, Wittig S, Cario G, Viehmann S, Mueller A, Gruhn B, Haefer R, Zintl F, Sauerbrey A (2003) The multidrug resistance associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 102:4493–4498
Den Boer ML, Rieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers G-J-L, Janka-Schaub G, Henze G, Veerman AJP (1998) Relationship between major vault resistance protein, MRP, P-gp expression and drug resistance in childhood leukemia. Blood 91:2092–2098
Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD, Pieters R (2004) Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18:78–83
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–15670
Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358
Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA (1999) Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91:429–433
Xu J, Liu Y, Yang Y, Bates S, Zhang JT (2004) Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 279:19781–19789
Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T (2001) The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 33:503–511
Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH (2000) Transport of topoisomerase inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 922:188–194
Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan selected ovarian tumor cell line. Cancer Res 59:4559–4563
Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miake K, Resau JH, Bates S (2000) The multidrug resistant phenotype associated with overexpression of a new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011–2021
Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCPI), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145–152
Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485–1495
Burger H, Van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104:2940–2942
Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507–512
Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side population phenotype. Nat Med 7:1028–1034
Schinkel AH (2003) Mammalian ABC transporters involved in drug resistance, pharmacokinetics and detoxification. ABC2003 FEBS Advanced Lecture Course (2003), p 60
Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van de Vijver MJ, Scheper RJ, Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458–3464
Plasschaert SL, van der Kolk DM, de Bont ES, Kamps WA, Morisaki K, Bates SE, Scheffer GL, Scheper RJ, Vellenga E, de Vries EG (2003) The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res 9:5171–5177
Ross DD, Karp JE, Chen TT, Doyle LA (2000) Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96:365–368
Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F (2002) Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 118:147–150
Van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, Van den Holt B, Pieters R, Sonneveld P (2002) Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory myeloid leukemia (AML). Leukemia 16:833–839
Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635–6659
Allen JD, Jackson SC, Schinkel AH (2002) A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res 62:2294–2299
Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 62:5035–5040
Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048–4054
Bertino JR (1993) Ode to methotrexate. J Clin Oncol 11:5-14
Peters GJ, Schornagel JH, Milano GA (1993) Clinical pharmacokinetics of anti-metabolites. Cancer Surv 17:123–156
Purcell WT, Ettinger DS (2003) Novel antifolate drugs. Curr Oncol Rep 5:114–125
Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532–2535
Sirotnak FM, Wendel HG, Bornmann WGB, Tong WP, Miller VA, Scher HI, Kris MG (2000) Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res 6:3705–3712
Kusuhara H, Suzuki H, Naito M, Tsuruo T, Sugiyama Y (1998) Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharmacol Exp Ther 285:1260–1265
Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6914–6919
Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144–3150
Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD (2001) Transport of methotrexate (MTX) and folates by the multidrug resistance protein (MRP3 and MRP 1) effect of polyglutamylation on MTX transport. Cancer Res 61:7225–7232
Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J (1997) Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta 1326:12–22
Ito K, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, Cole SP (2001) Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem 276:38108–38114
Lee K, Klein-Szanto AJ, Kruh GD (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 92:1934–1940
Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, Schneider E (2000) Methotrexate cross-resistance in a mitoxantrone selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 60:3514–3521
Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG (2005) ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 65:8414–8422
Sirotnak FM (1985) Obligate genetic expression in tumor cells of a fetal membrane property mediating “folate” transport: biological significance and implications for improved therapy of human cancer. Cancer Res 45:3992–4000
Sirotnak FM, Tolner B (1999) Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 19:91–122
Sierra EE, Goldman ID (1999) Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin Oncol 26(2 Suppl 6):11–23
Henderson GB (1990) Folate-binding proteins. Annu Rev Nutr 10:319–335
Kamen B (1997) Folate and antifolate pharmacology. Semin Oncol 24(5 Suppl 18):S18–S39
Matherly LH, Goldman ID (2003) Membrane transport of folates. Vitam Horm 66:403–456
Westerhof GR, Jansen G, van Emmerik N, Kathmann I, Rijksen G, Jackman AL, Schornagel JH (1991) Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res 51:5507–5513
Westerhof GR, Schornagel JH, Rijnboutt S, Pinedo HM, Jansen G (1993) Identification of a reduced folate/methotrexate carrier in human KB-cells expressing high levels of membrane associated folate binding protein. Adv Exp Med Biol 338:771–774
Westerhof GR, Rijnboutt S, Schornagel JH, Pinedo HM, Peters GJ, Jansen G (1995) Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Cancer Res 55:3795–3802
McGuire JJ, Hsieh P, Coward JK, Bertino JR (1980) Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J Biol Chem 255:5776–5788
Zhao R, Gao F, Hanscom M, Goldman ID (2004) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718–727
McGuire JJ, Bertino JR (1981) Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem 38:19–48
Cook JD, Cichowicz DJ, George S, Lawler A, Shane B (1987) Mammalian folylpoly-gamma-glutamate synthetase. 4. In vitro and in vivo metabolism of folates and analogues and regulation of folate homeostasis. Biochemistry 26:530–539
Lowe KE, Osborne CB, Lin BF, Kim JS, Hsu JC, Shane B (1993) Regulation of folate and one-carbon metabolism in mammalian cells. II. Effect of folylpoly-gamma-glutamate synthetase substrate specificity and level on folate metabolism and folylpoly-gamma-glutamate specificity of metabolic cycles of one-carbon metabolism. J Biol Chem 268:21665–21673
Osborne CB, Lowe KE, Shane B (1993) Regulation of folate and one-carbon metabolism in mammalian cells. I. Folate metabolism in Chinese hamster ovary cells expressing Escherichia coli or human folylpoly-gamma-glutamate synthetase activity. J Biol Chem 268:21657–21664
Moran RG (1999) Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 26(2 Suppl 6):24–32
Scott JM (1992) Folate-vitamin B12 interrelationships in the nervous system. Proc Nutr Soc 51:219–224
Jhaveri MS, Wagner C, Trepel JB (2001) Impact of extrecellular folate levels on global gene expression. Mol Pharmacol 60:1288–1295
Zingg JM, Jones PA (1997) Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 18:869–882
Wills L (1931) Treatment of ‘pernicious anaemia of pregnancy’ and ‘tropical anaemia’ with special reference to yeast extract as curative agent. Br Med J I:1059–1064
Chanarin I (1979) In: Megaloblastic anaemias, 2nd edn. Blackwell, Oxford
Scott JM, Weir DG (1994) Folate/Vitamin B 12 interrelationships. Essays Biochem 28:63–72
Stanger O (2002) Physiology of folic acid in health and disease. Curr Drug Metab 3:211–223
Rampersaud GC, Kauwell GP, Bailey LB (2003) Folate: a key to optimizing health and reducing disease risk in the elderly. J Am Coll Nutr 22:1–8
Haynes WG (2002) Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 16:391–399
Kim YI (2003) Role of folate in colon cancer development and progression. J Nutr 133(11 Suppl 1):3731S–3739S
Choi SW, Mason JB (2000) Folate and carcinogenesis: an integrated scheme. J Nutr 130:129–132
Choi SW, Mason JB (2002) Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 132(8 Suppl):2413S–2418S
Prinz-Langenohl R, Fohr I, Pietrzik K (2001) Beneficial role for folate in the prevention of colorectal and breast cancer. Eur J Nutr 40:98–105
Mason JB (2002) Nutritional chemoprevention of colon cancer. Semin Gastrointest Dis 13:143–153
Selhub J (2002) Folate, vitamin B 12 and vitamin B6 and one carbon metabolism. J Nutr Health Aging 6:39–42
De Bree A, van Dusseldorp M, Brouwer IA, van het Hof KH, Steegers-Theunissen RP (1997) Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 51:643–660
Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22:517–528
Rots MG, Pieters R, Peters GJ, Noordhuis P, Van Zantwijk CH, Kaspers GJL, Hahlen K, Creutzig U, Veerman AJP, Jansen G (1999) Role of folylpolyglutamate synthetase and folylpolyglutarnate hydrolase in methotrexate accumulation and polyglutarnylation in childhood leukemia. Blood 93:1677–1683
McGuire JJ (2003) Anticancer antifolates: current status and future directions. Curr Pharm Des 9:2593–2613
Zhao R, Goldman ID (2003) Resistance to antifolates. Oncogene 22:7431–7457
Schimke RT (1986) Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer Res 56:1912–1917
Li WW, Lin JT, Tong WP, Trippett TM, Brennan MF, Bertino JR (1992) Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res 52:1434–1438
McCloskey DE, McGuire JJ, Russell CA, Rowan BG, Bertino JR, Pizzorno G, Mini E (1991) Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 266:6181–6187
Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, Buck S, Wright JE, Rosowsky A (1995) Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85:500–509
Hill BT, Bailey BD, White JC, Goldman ID (1979) Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate. Cancer Res 39:2440–2446
Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041–1048
Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Schornagel JH, Pinedo HM, Peters GJ, Assaraf YG (1998) Structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273:30189–30198
Jansen G, Barr HM, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Peters GJ, Assaraf YG (1999) Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 55:761–769
Tse A, Moran RG (1998) Cellular folates prevent polyglutamylation of 5,10-dideaza-tetrahydrofolate. J Biol Chem 273:25944–25952
Faessel HM, Slocum HK, Jackson RC, Boritzski TJ, Rustum YM, Nair MG, Greco WR (1998) Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring requiring enzymes: the critical role of polyglutamylation. Cancer Res 58:3036–3050
Assaraf YG, Goldman ID (1997) Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol Chem 272:17460-17466
Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB (1996) Augmentation of the therapeutic activity of lometrexol-(6-R)5,10-dideazatetreahydrofolate by oral folic acid. Cancer Res 15:2331–2335
Smith GK, Amyx H, Boytos CM, Duch DS, Ferone R, Wilson HR (1995) Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res 55:6117–6125
Schmitz JC, Grindey GB, Schultz RM, Priest DG (1994) Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationships to di deazatetra hydrofolate sensitivity. Biochem Pharmacol 48:319–325
Kusuhara H, Han Yhm Shimoda M, Kokue E, Suzuki H, Sugiyama Y (1998) Reduced folate derivatives are endogenous substrates for cMOAT in rats. Am J Physiol 275:G789–G796
Van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ (2001) Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 61:3675–3681
Zervos PH, Allen RH, Thornton DE, Thiem PA (1997) Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Eur J Cancer (suppl)33:S18
Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P, Bunn PA Jr (2002) Pemetrexed safety and dosing strategy. Sem Oncol 6(Suppl 18) 24–29
Peters GJ, Jansen G (2001) Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition 17:737–738
Bertino JR (1977) “Rescue” techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. Semin Oncol 4:203–216
Calvert H (2003) Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer. Semin Oncol 30(2 Suppl 3):2–5
Vogelzang NJ, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural meso-thelioma. J Clin Oncol 21:2636–2644
Stark M, Rothem L, Jansen G, Scheffer GL, Goldman ID, Assaraf YG (2003) Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol Pharmacol 64:220–227
Hooijberg JH, Peters GJ, Assaraf YG, Kathmann I, Priest DG, Bunni MA, Veerman AJ, Scheffer GL, Kaspers GJ, Jansen G (2003) The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem Pharmacol 65:765–771
Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG (2004) Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 279:25527–25534
Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I, Dijkmans BA, Peters GJ, Jansen G (2003) Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem 278:6680–6686
Hooijberg JH, Jansen G, Assaraf YG, Kathmann I, Pieters R, Laan AC, Veerman AJP, Kaspers GJ, Peters GJ (2004) Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol 67:1541–1548
Acknowledgment
We thank Dr. R. Honeywell for critically reading the paper. This study was supported by the Dutch Cancer Society (grant NKB-VU 2000-2237)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hooijberg, J.H., de Vries, N.A., Kaspers, G.J.L. et al. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 58, 1–12 (2006). https://doi.org/10.1007/s00280-005-0141-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0141-1